Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Functional and Presentation Currency (Details)

v3.24.2.u1
Summary of Significant Accounting Policies - Functional and Presentation Currency (Details)
 12 Months Ended
Mar. 31, 2024
Virax Biolabs Group Limited  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency U.S. dollars
Virax Biolabs (UK) Limited  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency British Pound Sterling
Virax Biolabs Group Limited  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency U.S. dollars
Virax Immune T- Cell Medical Device Company Limited  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency U.S. dollars
Virax Biolabs Pte. Limited  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency U.S. dollars
Logico Bioproducts Corp.  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency U.S. dollars
Shanghai Xitu Consulting Co., Limited  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency Renminbi
Virax Biolabs USA Management, Inc.  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency U.S. dollars
Virax Biolabs Group Holdings Ltd  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency British Pound Sterling
Virax Biolabs FZ-LLC  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency United Arab Emirates Dirhams
Virax Biolabs Trading B.V.  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency Euro
Virax Biolabs UK Operating LLC  
Disclosure of reclassifications or changes in presentation [line items]  
Functional Currency British Pound Sterling